As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Corvus Pharmaceuticals Inc. The largest reported stake is Orbimed Advisors LLC's, at 10.3%. 12 filings are on record since August 14, 2025 (Schedule 13D/A, January 27, 2026).
Sell to companies like Corvus Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 4,373,218 · Sole dispositive: 0 · Shared dispositive: 4,474,091 · SCHEDULE 13G, 2026-08-07
- · Reporting person: BlackRock, Inc. · Sole voting: 6,217,422 · Shared voting: 0 · Sole dispositive: 6,325,157 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-27
- · Holder: Sirenia Capital Management LP · Percent: 7.5% · SCHEDULE 13G
- · Holder: Point72 Asset Management, L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: BlackRock, Inc. · Percent: 6.4% · SCHEDULE 13G/A
Corvus Pharmaceuticals Inc has 12 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Orbimed Advisors LLC | 10.3% | 8,609,091 | SCHEDULE 13D/A, 2026-01-27 | 2026-01-23 |
| 7.8% | 6,085,922 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 | |
| BlackRock, Inc. | 7.5% | 6,325,157 | SCHEDULE 13G/A, 2026-07-27 | 2026-06-30 |
| Sirenia Capital Management LP | 7.5% | 6,831,828 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| State Street Corporation | 5.3% | 4,474,091 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Adams Street Partners, LLC | 3.9% | 3,275,616 | SCHEDULE 13D/A, 2026-02-05 | 2026-01-23 |
| Samlyn Capital, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
| Point72 Asset Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Corvus Pharmaceuticals Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Corvus Pharmaceuticals Inc and the records around it.
Corvus Pharmaceuticals Inc elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- SAMLYN CAPITAL, LLC also filed stake reports on 2 other companies: PureCycle Technologies, Inc. (May 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Watch Corvus Pharmaceuticals Inc
Get an email when Corvus Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Corvus Pharmaceuticals Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Corvus Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Corvus Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,217,422 | 0 | 6,325,157 | 0 | SCHEDULE 13G/A, 2026-07-27 |
| State Street Corporation | 0 | 4,373,218 | 0 | 4,474,091 | SCHEDULE 13G, 2026-08-07 |
The latest filing identifies Corvus Pharmaceuticals Inc by CUSIP 221015100 and gives its principal executive office as 863 MITTEN ROAD SUITE 102, BURLINGAME, CA 94010 (SCHEDULE 13G, 2026-08-07).
Purpose of Transaction (Item 4)
Orbimed Advisors LLC
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Amendment No. 12, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-01-27; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Samlyn Capital, LLC | 0% | SCHEDULE 13G/A |
| 2025-10-17 | BlackRock, Inc. | 5.4% | SCHEDULE 13G |
| 2026-01-27 | Orbimed Advisors LLC | 10.3% | SCHEDULE 13D/A |
| 2026-01-30 | The Vanguard Group | 5.18% | SCHEDULE 13G |
| 2026-02-05 | Adams Street Partners, LLC | 3.9% | SCHEDULE 13D/A |
| 2026-02-13 | Richard A. Miller | 7.8% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-27 | BlackRock, Inc. | 6.4% | SCHEDULE 13G/A |
| 2026-05-15 | Sirenia Capital Management LP | 7.5% | SCHEDULE 13G |
| 2026-05-15 | Point72 Asset Management, L.P. | 0% | SCHEDULE 13G/A |
| 2026-07-27 | BlackRock, Inc. | 7.5% | SCHEDULE 13G/A |
| 2026-08-07 | State Street Corporation | 5.3% | SCHEDULE 13G |
Questions about who owns Corvus Pharmaceuticals Inc
Who owns Corvus Pharmaceuticals Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Corvus Pharmaceuticals Inc: Orbimed Advisors LLC (10.3%, Schedule 13D/A, filed 2026-01-27), Richard A. Miller (7.8%, Schedule 13G/A, filed 2026-02-13), BlackRock, Inc. (7.5%, Schedule 13G/A, filed 2026-07-27), Sirenia Capital Management LP (7.5%, Schedule 13G, filed 2026-05-15) and State Street Corporation (5.3%, Schedule 13G, filed 2026-08-07).
Who are the largest shareholders of Corvus Pharmaceuticals Inc?
By the share each holder's latest filing reports, the largest holders of Corvus Pharmaceuticals Inc on this page are Orbimed Advisors LLC (10.3%), Richard A. Miller (7.8%) and BlackRock, Inc. (7.5%).
When did Orbimed Advisors LLC buy into Corvus Pharmaceuticals Inc?
The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D/A, filed 2026-01-27, reporting 10.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Corvus Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 22, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 23, 2026 | Leadership change: Andrew C. Chan appointed | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Corvus Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.